Haemonetics (NYSE:HAE) Given Buy Rating at BTIG Research

Haemonetics (NYSE:HAE)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a report issued on Friday,Benzinga reports. They currently have a $88.00 price target on the medical instruments supplier’s stock. BTIG Research’s price objective points to a potential upside of 4.70% from the stock’s previous close.

A number of other equities analysts have also weighed in on HAE. Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Mizuho boosted their price objective on shares of Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Raymond James Financial restated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th. Robert W. Baird upped their price target on shares of Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Finally, Citigroup decreased their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.10.

Haemonetics Stock Up 1.3%

NYSE:HAE opened at $84.05 on Friday. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The firm’s 50-day moving average price is $77.02 and its 200-day moving average price is $65.90. The company has a market capitalization of $3.93 billion, a PE ratio of 24.58, a P/E/G ratio of 1.56 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter in the prior year, the firm posted $1.12 earnings per share. The business’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities analysts predict that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Several institutional investors have recently modified their holdings of HAE. True Wealth Design LLC raised its position in shares of Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 335 shares during the last quarter. Central Pacific Bank Trust Division lifted its stake in shares of Haemonetics by 2.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock worth $713,000 after buying an additional 188 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Haemonetics during the third quarter worth about $233,000. CIBC Private Wealth Group LLC raised its holdings in Haemonetics by 69.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 448 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in Haemonetics in the 3rd quarter worth approximately $251,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.